Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lan Su

Showing results (341-350 of 345) with videos related to

Pageof 35
Sort By:
You have reached the last page of results.This site can display upto 345 results.
Scientific Reports|March 1, 2022
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapyPo-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Journal of the National Cancer Institute|January 27, 2017
Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node MetastasesXin Gao, Liao-Yuan Li, Jörg Rassler, et al.
Therapeutic Advances in Medical Oncology|June 7, 2021
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 studyYen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, et al.
Cancer Medicine|July 28, 2025
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based TherapiesMingjia Li, Po-Lan Su, Songzhu Zhao, et al.
Pageof 35

Showing results (341-350 of 345) with videos related to

Sort By:
Pageof 35
You have reached the last page of results.This site can display upto 345 results.
Scientific Reports|March 1, 2022
The impact of driver mutation on the treatment outcome of early-stage lung cancer patients receiving neoadjuvant immunotherapy and chemotherapyPo-Lan Su, Jung-Yueh Chen, Chang-Yao Chu, et al.
Investigational New Drugs|December 3, 2025
Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancerDwight H Owen, Ruohan Wu, Lai Wei, et al.
Journal of the National Cancer Institute|January 27, 2017
Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node MetastasesXin Gao, Liao-Yuan Li, Jörg Rassler, et al.
Therapeutic Advances in Medical Oncology|June 7, 2021
The relative importance of predictive factors for single first-generation EGFR-TKI use for more than 5 years in patients with advanced non-small cell lung cancer: Taiwan multicenter TIPS-5 studyYen-Hsiang Huang, Jen-Yu Hung, How-Wen Ko, et al.
Cancer Medicine|July 28, 2025
Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based TherapiesMingjia Li, Po-Lan Su, Songzhu Zhao, et al.
Pageof 35